We advised the sole underwriter on the offering

Davis Polk advised the sole underwriter in an SEC-registered offering by Maze Therapeutics, Inc. of 5,540,000 shares of common stock and pre-funded warrants to purchase 850,000 shares of its common stock, generating gross proceeds of approximately $150 million. Maze is listed on Nasdaq under the symbol “MAZE.”

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases, including obesity.

The Davis Polk capital markets team included partner Emily Roberts and associates Rebecca Lei and Matthew Kenney. Counsel Dustin Plotnick and associate Carter Ballentine Allison provided tax advice. Partner David R. Bauer and associate Shreya R. Kundur provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post